Literature DB >> 32277685

ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 Gene Polymorphisms Contribute to Subsceptibility of Colon, Gastric, HCC, Lung And Prostate Cancer.

Eda Balkan1, Mehmet Bilici, Betul Gundogdu, Nurhak Aksungur, Asli Kara, Ezgi Yasar, Hasan Dogan, Gurkan Ozturk.   

Abstract

PURPOSE: Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The relationship between genetic polymorphisms and cancer risk has been extensively researched. In the present study, we evaluated the association between polymorphisms in two DNA repair genes, ERCC2 Lys751Gln (rs13181) and XRCC2 Arg188His (rs3218536) and the risk of colorectal, stomach, HCC, prostate and lung cancer.
METHODS: This study was planned by the Medical Biology Unit and Department of Internal Medicine, Pathology and Surgical Medicine Sciences of Ataturk University. A total of 40 colon cancer, 40 gastric cancer, 40 hepatocellular carcinoma (HCC), 40 prostate cancer, and 40 lung cancer patients and 40 healthy individuals over 18 years of age were enrolled in the study (Controls). All patients and healthy subjects underwent ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 genotyping. After collection of 10 ml venous blood from the patients, DNA was isolated and single nucleotide polymorphism (SNP) analysis was performed using Roche 480 Real-Time PCR device. Results were analyzed using SPSS version 23.0 software.
RESULTS: There were statistically significant differences in ERCC2 Lys751Gln rs13181 polymorphism variants GG colon and GT in the colon control and GG,TTprostate cancer groups when compared with the control group.. GG variant of XRCC2 Arg188 rs3218536 was higher in the gastric patient group. AG variant of XRCC2 Arg188 rs3218536 was higher in gastric control group
Conclusion: The results of the present study demonstrate that ERC22 Lys751Gln polymorphisms may be associated with the development of colon and prostate cancers in the Turkish population. This was a small-scale study, and the results should be corroborated with further research including larger groups of patients with each cancer type and more healthy controls.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32277685

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  5 in total

1.  The link of ERCC2 rs13181 and ERCC4 rs2276466 polymorphisms with breast cancer in the Bangladeshi population.

Authors:  Shaid All Sahaba; Mohammad Abdur Rashid; Md Saiful Islam; Noor Ahmed Nahid; Mohd Nazmul Hasan Apu; Taposhi Nahid Sultana; Nusrat Islam Chaity; Md Mehedi Hasan; Mohammad Safiqul Islam
Journal:  Mol Biol Rep       Date:  2021-11-26       Impact factor: 2.316

2.  Association of DNA Repair Genes XRCC1 and APE-1 with the Risk of Cervical Cancer in North Indian population.

Authors:  Mark Rector Charles; Syed Tasleem Raza; Rolee Sharma; Pushpendra Pratap; Ale Eba; Manvendra Singh
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

Review 3.  Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma.

Authors:  Mohammed A Alshehri; Moath M Alshehri; Naif N Albalawi; Moshari A Al-Ghamdi; Mohammed M H Al-Gayyar
Journal:  Oncol Lett       Date:  2021-01-04       Impact factor: 2.967

4.  Impact of Polymorphism in Base Excision Repair and Nucleotide Excision Repair Genes and Risk of Cervical Cancer: A Case-Control Study.

Authors:  Kailas D Datkhile; Pratik P Durgawale; Madhavi N Patil; Rashmi A Gudur; Anand K Gudur; Satish R Patil
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

5.  Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil.

Authors:  Steffany Larissa Galdino Galisa; Priscila Lima Jacob; Allysson Allan de Farias; Renan Barbosa Lemes; Leandro Ucela Alves; Júlia Cristina Leite Nóbrega; Mayana Zatz; Silvana Santos; Mathias Weller
Journal:  Genet Mol Biol       Date:  2022-02-02       Impact factor: 1.771

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.